Skip to main content

Table 1 Baseline characteristics of patients switching from NPH to glargine

From: Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study

  Type 1 Type 2
n (%) 304 (43.4) 397 (56.6)
% male 47.4 52.4
Age (years)* 34.8 ± 13.2 48.2 ± 13.8
Weight (kg) 76.6 ± 14.7 82.9 ± 16.7
Baseline HbA1c*† 8.8 ± 1.5 8.9 ± 1.4
Duration of diabetes (years) ‡ 13.4 ± 10.0 10.0 ± 8.6
Number of co-morbidities*§ 1.7 ± 1.3 1.9 ± 1.3
Proportion of patients receiving OAD(s) (%) 2 22
OAD per patient before starting insulin*¶ 0.0 ± 0.0 0.2 ± 0.4
Proportion of patients receiving bolus doses (%)   
   At any point in prior 12 months 97 91
   In prior 3 months 79 80
Hypoglycaemia episodes in a 3 month period*||   
   No. episodes 36 40
   Mean no. episodes per patient 0.12 0.10
  1. OAD = oral antidiabetic drugs; HbA1c = glycated haemoglobin. Data are mean ± SD unless indicated.
  2. *Significant variables investigated in multivariate analysis.
  3. †Data missing for 30 patients with type 1 diabetes and 39 patients with type 2 diabetes.
  4. ‡Data missing for 3 patients with type 1 diabetes and 8 patients with type 2 diabetes.
  5. §Includes myocardial infarction, stroke, peripheral vascular disease, neuropathy, nephropathy, and retinopathy. Data available for 57 patients with type 1 diabetes and 76 patients with type 2 diabetes.
  6. ¶Number of oral diabetic treatments (e.g. metformin, sulfonylureas) prescribed prior to commencing insulin. Data missing for 100 patients with type 2 diabetes.
  7. ||Number of hypoglycaemic episodes reported during the 3 month period prior to switch. Hypoglycaemic episodes were reported in 30 patients with type 1 diabetes and 33 patients with type 2 diabetes.
Back to article page